# Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Source: https://onco.cc/trials/nct06745882/  
OnCo record `nct06745882` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cisplatin, carboplatin, pemetrexed, pembrolizumab and other drugs in lung cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.

## Summary

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC is a phase 2, interventional study registered as NCT06745882 by H. Lee Moffitt Cancer Center and Research Institute, with a registry enrolment figure of 318 participants, started 2025-06-13 and due to reach its primary completion in 2030-01. Interventions recorded: Cisplatin; Carboplatin; Pemetrexed; Pembrolizumab; Abraxane; Paclitaxel. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Cohort 1: Real World Overall Survival (rwOS); Cohort 2 Arm A: Progression Free Survival (PFS); Cohort 2 Arm B: Progression Free Survival (PFS). Lung eligibility wording from the registry: "* Have histologically or cytologically confirmed, advanced/metastatic NSCLC". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06745882
- Phase: 2
- Setting: Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC
- Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Enrolled: 318

## Sources

- ClinicalTrials.gov NCT06745882: https://clinicaltrials.gov/study/NCT06745882

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06745882.json